Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
Jordi Remón, Jean‐Charles Soria, Solange Peters
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1637-1642
Open Access | Times Cited: 272

Showing 1-25 of 272 citing articles:

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 10, pp. 1274-1286
Closed Access | Times Cited: 461
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 2, pp. 137-147
Closed Access | Times Cited: 332
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 18, pp. 1672-1684
Open Access | Times Cited: 276
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S. Herbst, Yi‐Long Wu, Thomas John, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 10, pp. 1830-1840
Open Access | Times Cited: 229
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Nicolas Girard, Jair Bar, Pilar Garrido, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 2, pp. 181-193
Open Access | Times Cited: 145
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 14, pp. 1265-1276
Closed Access | Times Cited: 133
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
Shun Lu, Terufumi Kato, Xiaorong Dong, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 7, pp. 585-597
Closed Access | Times Cited: 89
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Marina Chiara Garassino, Julien Mazières, Martin Reck, et al.
Journal of Thoracic Oncology (2022) Vol. 17, Iss. 12, pp. 1415-1427
Open Access | Times Cited: 80
Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel
Mário Sousa‐Pimenta, Letı́cia M. Estevinho, Agnieszka Szopa, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 51
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective
Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100841-100841
Open Access | Times Cited: 20
Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions
Huatao Zhou, Zilong Zheng, Chengming Fan, et al.
Seminars in Cancer Biology (2025) Vol. 109, pp. 44-66
Closed Access | Times Cited: 2
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 2
Updated Prognostic Factors in Localized NSCLC
Simon Garinet, Pascal Wang, Audrey Mansuet‐Lupo, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1400-1400
Open Access | Times Cited: 64
[18F]FDG-PET/CT Radiomics and Artificial Intelligence in Lung Cancer: Technical Aspects and Potential Clinical Applications
Reyhaneh Manafi‐Farid, Emran Askari, Isaac Shiri, et al.
Seminars in Nuclear Medicine (2022) Vol. 52, Iss. 6, pp. 759-780
Open Access | Times Cited: 54
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives
Jay M. Lee, Ciaran McNamee, Eric M. Toloza, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 11, pp. 1458-1477
Open Access | Times Cited: 37
Selective Mediastinal Lymph Node Dissection Strategy for Clinical T1N0 Invasive Lung Cancer: A Prospective, Multicenter, Clinical Trial
Yang Zhang, Chaoqiang Deng, Qiang Zheng, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 7, pp. 931-939
Open Access | Times Cited: 34
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe
Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100840-100840
Open Access | Times Cited: 15
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC
Martin Reck, Ernest Nadal, Nicolas Girard, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 6, pp. 587-593.e3
Closed Access | Times Cited: 12
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
Andrea Riccardo Filippi, Jair Bar, C. Chouaid, et al.
ESMO Open (2024) Vol. 9, Iss. 6, pp. 103464-103464
Open Access | Times Cited: 11
Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Peter S.N. van Rossum, Nienke Wolfhagen, Liselotte W. van Bockel, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. 1550-1563
Closed Access | Times Cited: 8
Implementation of the 9th TNM for lung cancer: practical insights for radiologists
Gianluca Argentieri, Camilla Valsecchi, Francesco Petrella, et al.
European Radiology (2025)
Open Access | Times Cited: 1
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
Elvis Ruznic, Marisa Klebermass, Barbara Zellinger, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 945-945
Open Access | Times Cited: 1
Study on postoperative survival prediction model for non-small cell lung cancer: application of radiomics technology workflow based on multi-organ imaging features and various machine learning algorithms
Hanlin Wang, Hong Yuan, Zimo Zhang, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 1
Advances of PET/CT in Target Delineation of Lung Cancer Before Radiation Therapy
Cedric Richlitzki, Farkhad Manapov, Adrien Holzgreve, et al.
Seminars in Nuclear Medicine (2025) Vol. 55, Iss. 2, pp. 190-201
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top